Clinical ink Targets 67% Obesity Drug Drop-Off With Behavioral Data
Toronto – October 14, 2026 -- Real-world discontinuation of weight-loss medications can reach 67% within 12 months, while clinical trials show sustained weight reduction of 15–22% over 72 weeks, according to materials for an Xtalks webinar featuring Clinical ink executives on October 29.
Psychology, not only side effects, drives discontinuation of obesity therapy
Side effects, cost and access explain only part of the drop-off, the organizers state. Confidence, doubt and treatment identity are increasingly recognized as independent predictors of discontinuation. Motivations differ by patient, rooted in appearance, day-to-day function or long-term health risk.
Most patient support programs have no validated way to identify behavioral risk before it affects outcomes, creating a gap for pharma teams managing obesity portfolios.
